EFTA00593714.pdf

FOCUSED ULTRASOUND FOUNDATION Focused Ultrasound The Technology Focused ultrasound is an early-stage, disruptive, noninvasive therapeutic technology with the potential to improve the lives of millions of patients with a variety of serious medical disorders by providing an alternative or complement to surgery, radiation therapy, drug delivery and cancer immunotherapy. This game changing technology has the potential to increase the quality and longevity of life and decrease the cost of care for countless patients by transforming the treatment of a range of conditions including tumors of the brain, breast, prostate, liver and pancreas; Parkinson's and Alzheimer's disease and epilepsy; depression and obsessive compulsive disorder; and arthritis and hypertension. With further technological development, laboratory research and clinical trials focused ultrasound could be as revolutionary to therapy as MR scanning has been to diagnosis. Focused ultrasound treats tissue with multiple intersecting beams of high-frequency sound focused accurately on targets deep in the body without damaging surrounding structures, much like beams of light can be focused on a point with a magnifying glass. At the focal point where the beams converge the ultrasound energy induces a variety of biological effects including destroying tissue, delivering drugs in high concentrations, enhancing radiation therapy and stimulating the immune response.The multiple biological effects create the possibility to treat a wide range of disorders. Magnetic resonance or ultrasound imaging is used to identify the targets and guide and control the treatment in real time. The Problem Unfortunately, it can take decades for a new therapeutic technology like focused ultrasound to become mainstream. Every year we shave off that process could reduce death, disability and suffering for countless people. The Focused The Foundation is a unique medical research, education, and advocacy organization created as the catalyst to accelerate the development and adoption of focused ultrasound. The Foundation is Ultrasound Foundation a tax-exempt 501(c)(3) corporation started in 2006. To achieve its goals, the Foundation utilizes an approach that is entrepreneurial, high-impact, high performance, market-driven and results oriented. We advance the field by leveraging opportunities and overcoming barriers, thereby shortening the time from laboratory research to widespread patient treatment as a standard of care. Major initiatives include • Influendng the direction of the field, identifying priorities and defining areas of clinical benefit • Fostering collaboration and stimulating innovation • Providing resources, both financial and human capital • Creating knowledge by organizing, conducting and funding research • Aggregating and sharing knowledge through our website, newsletter, social media, webinars, and open-source journal Overcoming barriers, induding regulatory and reimbursement challenges Cultivating the next generation of researchers by supporting internships and fellowships Convening the community through meetings, symposia, and workshops Increasing awareness through events and media outreach This work is made possible by the philanthropic support of our donors, who recognize the urgent needs of patients, the potential of focused ultrasound and the value of the Foundation's disciplined, entrepreneurial approach. Focused Ultrasound Foundation For more information, visit www.fusfoundation.org or contact, Nora Seilheimer, 1230 Cedars Court , Suite 206 I Charlottesville, VA 22903 I EFTA00593714 Mechanisms of Action Focused ultrasound is a platform technology that affects tissue through multiple mechanisms, thereby enabling the treatment of a wide variety of medical disorders. TISSUE DESTRUCTION DRUG DELIVERY IMMUNOMODULATION RADIOSENSITIZATION Thermal ablation Increased vascular permeability Release of tumor antigens Non-lonLting alternative to Mechanical cellular damage Localized drug release from Increased immunotherapeutic radiotherapy nanoparticles delivery Tissue preconditioning Microvascular disruption Disruption of cell membranes Increased immune cell trafficking to tumors Adoption Status This chart portrays the global status of focused ultrasound as it evolves to widespread adoption. The number of indications is increasing rapidly, but most are in the early stages of development =1=1= Neurological Ontological Cardiovascular • rwoll < MOO • 4, 3 t 'on Futurn LKIerry Deep "en Throntolo Wenn • DeprySaiWr .... liver COnCw MIMS • Noon bock OCD Poucreolic [grow Hihl no • MEMM • Yerpormaoi Amen, Nem, Atinomers IMe., Soli Dixon rumen ono n Stolid Per 100.0., ElOrirrniv MM M &On kenCIS Perliolrk NEVOISCrtrury,., ono , setkOCODN)ks M. no Urolosecal Murrouue Wen>, hood & Neck Omer lung Cancer ma • Proyfule Co-cer • Sfrcke liennwylic ?eon ME mu kidney cancer Milan V/ IngeereCi NOvoq. adorn taxer Bowel cancer on Barron neuritic trrporru.z. . S Coun Come. *COO (Wei infiv • AVM . , Ac ute NOM., Net • v.xnusiecy cance• Velvocele 810cIrlei Cain-' Musculoskeletal Women's Health MEM. • Viet e I r.ory. Endocrine Disorders ooi.,;.0 °vow.. . MIMES • Wen411tec.ccenc.ennt MMM. 00000rIreeis MOMS LilorVro AtIonomyout 04C 005400?‹, MO lut)01PrerrOuCv AMOY APOP, ve el SLrGerr Sociciklis OrcryanCcncet Spool Cord Injury pctecyslic Ovarian SOUVOMO MEI Miscellaneous Sneral lomon Mae • me ICA woe) nn tcusee !Avian, rasters r ZIS to anti te usono rot ret voters 'caner Neal F. Kassel', MD John FL Grisham Steve H. Rusckowski Board of Directors Chaim's\ Founder:FocusedUltrasound Author President and CEO, Quest Diagnostics Inc. Foundation Former CEO. Philips Healthcare William A. Hawkins, Ill Former Co-Chair ofNeurosurgery, Charles Steger, PhD Former Chairman & CEO,Medtronic University of Virgrna Former President, Virginia Tech Daniel P. Jordan, PhD Dorothy N. Batten President Emeritus, Thomas Jefferson Andrew C. von Eschenbach, MD Founder, 'Thrive Initiative President, Samaritan Health Initiative Foundation. Inc. Former Director, Larxlmark Former Comftssioner,U.S Food and Cornmunkations.inc Edward J."Ned" Kelly, Ill Drug Administration Former Chairman. Institutional Clients LodewijkJ.R. deVink Former Director. National Cancer Institute Group. Cliigroup FouncingPartner, Blackstone Healthcare Cad P. Zeithamt PhD Partners, LLC Edward D. Miller, MD Dean, University of VIrgina's hldntrre Former CEO. Johns Hopkins Medicine Former Chairman &CEO,Warner-Lamtert School of Commerce Eugene V. Fife Frederic H. Molt MD Co-Founder, Intuitive Surgical Founding PrincipalVawterCapItalLLC Chairman & CEO, AWIS Surgical Robotics, Inc. Former Chairman,Goldman Sachs Ind Council The Foundation's Council is a group of passionate, enthusiastic advocates who connect us to the greater community, share our story, and promote our mission. Jane P Batten, Co-chair Marguerite& Norwood Davis Lonna & Tony Mendez Alice H. Siegel Charles H. Serlheimer, Jr., Co-chair Diane Heller Michael Milken Aaron Stern, MD, PhD Cecelia S. Howell Pamela Minetti, MBA Howard & Fredi Stevenson John B. Adams, Jr. Ellen Block Dean L. Kamen Paula E Newcomb Jane Tolleson Ann Kingston Wyndham G. Robertson Meredith Jung-En Woo, PhD Charles F. Bryan, Jr. PhD T. Michael Cashman Syaru Shirley Lin, PhD Mary Lou Seilheirner Linda K. Zecher Nancy J. &Thomas N. Chevming Amanda Megargel Kimberly Skelly 3.112017 EFTA00593715